Investigational non-antibiotic therapeutics for infections in hematopoietic cell transplant recipients and patients with hematologic malignancies receiving cellular therapies

Transpl Infect Dis. 2023 Nov:25 Suppl 1:e14193. doi: 10.1111/tid.14193. Epub 2023 Nov 13.

Abstract

In the age of progressive antimicrobial resistance and increased difficulty combating infections in immunocompromised hosts, there has been renewed interest in the use of nontraditional therapeutics for infections. Herein, we review the use of investigational non-pharmaceutical anti-infective agents targeting fungal, bacterial, and viral infections in patients with hematologic malignancies, focusing on those receiving hematopoietic cell transplantation or cellular therapies. We discuss immune checkpoint inhibitors, granulocyte transfusions, bone marrow colony-stimulating factors, bacteriophages, fecal microbiota transplantation, and virus specific T-cell therapy. Although there is promising early experience with many of these treatments, further studies will be required to define their optimal role in the therapeutic armamentarium against infections in immunocompromised hosts.

Keywords: bacteriophage therapy; cellular therapy; checkpoint inhibitors; colony-stimulating factor; fecal microbiota transplant; granulocyte transfusion; hematopoietic cell transplant; virus-specific-T-cell therapy.

Publication types

  • Review

MeSH terms

  • Bone Marrow
  • Bone Marrow Transplantation
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Transplant Recipients

Substances

  • Granulocyte Colony-Stimulating Factor